PCSK9 Forum
12th June 2015
Facebook Twitter RSS YouTube
For latest updates
Register today
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact

Important week for PCSK9 inhibitors

The Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration has voted in favour of approving two PCSK9 inhibitors - evolocumab and alirocumab.

Earlier the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for the marketing of evolocumab.

Why are these new LDL-cholesterol lowering drugs so important?

Professor Philip Barter, President of the International Atherosclerosis Society, highlights the importance of PCSK9 inhibitors for patients with a high risk of cardiovascular events, especially those with familial hypercholesterolaemia.

Why are these new LDL-Cholesterol lowering drugs so important?

How will PCSK9 inhibitors be used in practice?  

How will PCSK9 inhibitors be used in practice?

Professor Steven Nicholls, Deputy Director and SAHMRI Heart Foundation Heart Health Theme Leader at the University of Adelaide, Australia, discusses the patients in whom these new treatments will be used initially and speculates on future practice.

Meet the Editors
Beginning a new era in cholesterol lowering therapy

Professor John Chapman and Professor Henry Ginsberg discuss how these innovative new drugs will shape the future management of patients with elevated LDL-cholesterol who are at high risk of cardiovascular events.

Many heart attack patients have FH

About one in 12 of the heart attack patients included in a major European survey probably have familial hypercholesterolaemia (FH).

New data from EUROASPIRE IV - the European Society of Cardiology survey of secondary prevention of coronary heart disease - reveals that 8.3% of patients who had heart attacks were likely to be suffering from FH.

In younger patients (<50 years) FH was believed to occur in one in five heart attack victims.

Many heart attack patients have FH

As a result, cardiologists are being urged to consider FH in every younger or middle-aged person who has a coronary event, according to Dr Joost Besseling, one of the authors.

Read more »

Read the EUROASPIRE IV report »

Urgent message

Identify children with FH
Start treatment early

Early identification and treatment of children with familial hypercholesterolaemia (FH) can allow them to achieve a normal lifespan.

  Early identification and treatment of children with familial hypercholesterolaemia

This is the exciting message of a newly published Position Statement on Paediatric Familial Hypercholesterolaemia presented by a Consensus Panel of the European Atherosclerosis Society (EAS) at the recent ISA Congress in Amsterdam.

Why do we need to treat children with FH?

Why do we need to treat children with FH?  

Dr Albert Wiegman of the Academic Medical Center, Amsterdam, The Netherlands, discusses the critical importance of targeting asymptomatic children with FH and the significant benefits of early intervention.

Read the full report »

Read the position paper in the EHJ »

PCSK9 Education and Research Forum

Invotation from John Chapman
Aims & Objectives video
Read our Mission Statement
Partnership and outreach
Meet our Editorial Board
View Forthcoming Meetings
Send an invitation to join PCSK9 Forum to your colleagues »
Send this email on to a colleague »
See more on pcsk9forum.org


Further reading

  YouTube Channel
For the latest videos, interviews and webcasts from leading experts.
  Follow us on Twitter
For updates on hot topics, PCSK9 news and conference reports.
  Like us on Facebook
For the latest updates on conferences, PCSK9 news and video reports.
  Supported by educational grants from: Amgen Lilly pFizer Sanofi  
Copyright PCSK9 Forum 2015. Please click here to unsubscribe from future mailings.